Cryo-Cell International, Inc. (CCEL) Stock

Cryo-Cell International, Inc., headquartered in Oldsmar, Florida, specializes in cellular processing and cryogenic storage, focusing on the collection and preservation of umbilical cord blood stem cells primarily for family use. The company offers a comprehensive cord tissue service that stores a segment of the umbilical cord, which contains valuable mesenchymal stem cells utilized in regenerative medicine treatments for conditions such as heart disease, kidney disease, ALS, wound healing, and autoimmune disorders. Additionally, Cryo-Cell manufactures and markets the PrepaCyte CB processing system, a technology essential for processing umbilical cord blood stem cells.

With a global repository storing approximately 500,000 cord blood and cord tissue stem cells, Cryo-Cell International markets its services directly to expectant parents and through partnerships with obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other healthcare professionals. The company's dedication to advancing stem cell preservation and regenerative medicine underscores its commitment to providing families with innovative healthcare options for future medical needs.

Incorporated in 1989, Cryo-Cell International continues to be a leader in the field of stem cell technology, leveraging its expertise to expand awareness and accessibility to cutting-edge cellular therapies worldwide. Its headquarters in Florida serve as a hub for advancing research, technology development, and customer-focused services in the field of cord blood and tissue banking.